Masimo Co. (NASDAQ:MASI) – Stock analysts at Piper Jaffray Companies upped their FY2019 earnings per share (EPS) estimates for Masimo in a report released on Monday, May 6th. Piper Jaffray Companies analyst W. Quirk now expects that the medical equipment provider will post earnings of $3.12 per share for the year, up from their prior forecast of $3.08. Piper Jaffray Companies currently has a “Overweight” rating and a $148.00 target price on the stock. Piper Jaffray Companies also issued estimates for Masimo’s Q4 2019 earnings at $0.89 EPS, Q1 2020 earnings at $0.93 EPS, FY2020 earnings at $3.62 EPS, FY2021 earnings at $4.21 EPS and FY2022 earnings at $4.84 EPS.
Masimo (NASDAQ:MASI) last released its earnings results on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 19.53% and a net margin of 22.55%. The business had revenue of $231.70 million during the quarter, compared to the consensus estimate of $223.67 million. During the same period last year, the company earned $0.75 earnings per share. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year.
Several other analysts also recently weighed in on MASI. Zacks Investment Research downgraded Masimo from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 31st. Needham & Company LLC restated a “buy” rating and issued a $139.00 price objective on shares of Masimo in a report on Friday, February 1st. Finally, BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price objective for the company. in a report on Tuesday, April 16th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $149.75.
MASI stock opened at $136.71 on Wednesday. The stock has a market capitalization of $7.28 billion, a P/E ratio of 45.12, a PEG ratio of 2.88 and a beta of 1.12. Masimo has a 1-year low of $95.53 and a 1-year high of $143.10.
A number of institutional investors and hedge funds have recently bought and sold shares of MASI. Claybrook Capital LLC purchased a new position in Masimo in the fourth quarter valued at about $25,000. West Oak Capital LLC purchased a new position in Masimo in the first quarter valued at about $28,000. Ruggie Capital Group purchased a new position in Masimo in the fourth quarter valued at about $33,000. Quantamental Technologies LLC purchased a new position in Masimo in the fourth quarter valued at about $43,000. Finally, Financial Gravity Companies Inc. purchased a new position in Masimo in the fourth quarter valued at about $49,000. Institutional investors own 83.16% of the company’s stock.
In other Masimo news, CAO Ramshorst David J. Van sold 1,845 shares of Masimo stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $140.00, for a total value of $258,300.00. Following the transaction, the chief accounting officer now owns 1,695 shares in the company, valued at $237,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the director now owns 74,832 shares in the company, valued at approximately $10,102,320. The disclosure for this sale can be found here. Insiders sold 33,722 shares of company stock valued at $4,582,310 over the last 90 days. 11.50% of the stock is currently owned by corporate insiders.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Read More: What are gap-down stocks?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.